By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Cannabis NewsCannabis News
Aa
  • Cannabis
  • CBD
  • Science
  • Culture & Arts
  • Cannabis Press Releases
  • More
    • About Maryjanes Post
    • Cannabis Advertising
    • Cannabis Partnerships
Reading: Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com
Share
Aa
Cannabis NewsCannabis News
Search
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • Topics
    • Business
    • Cannabis
    • Cannabis Tech
    • Culture & Arts
    • Industry Leaders
    • Cannabis Press Releases
  • About Maryjanes Post
    • Ambassador
    • Cannabis Partnerships
Follow US
  • Ad Choices
  • RSS Terms of Service
© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.
Cannabis News > Cannabis Press Releases > Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com
Cannabis Press Releases

Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com

Business Wire
Business Wire December 23, 2021
Updated 2021/12/23 at 6:04 PM
Share
SHARE

DUBLIN–(BUSINESS WIRE)–“The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering.

logo Cannabis Media & PR

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading.

- Advertisement -

In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals. In Europe however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals.

Companies Mentioned

  • Almirall
  • Bayer
  • C3 Cannabinoid Compound Company
  • Cronos
  • Ginkgo Bioworks
  • GW Pharmaceuticals
  • Novartis
  • Otsuka
  • PureForm Global

Findings in The Pharmaceutical Cannabis Report: 2nd Edition include:

  • The author estimates the market size for the three most widely used cannabinoid pharmaceuticals (Epidiolex, Sativex, Dronabinol) to be worth just under €900 million as of 2021, growing to €1.8 billion by 2025.
  • Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.
  • The current global spend on pain medications worldwide is estimated at US$63-85 billion each year. However, no single cannabinoid drug has received widespread approval in the treatment of pain.

The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol.

The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading.

The majority of medicinal cannabis is currently being prescribed in a medically non-traditional manner, with short patient-doctor interactions and approximate dosing of the active pharmaceutical ingredients (e.g., via inhalation of combusted flower). In both Europe and the United States (US), the sales of unapproved cannabis products such as smoked flower and full- spectrum oils dwarf those of approved pharmaceuticals like Epidiolex, Marinol, Sativex and Cesamet which have been guided through the traditional approvals process. In Europe however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as approved pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals, mainly Epidiolex.

- Advertisement -

Epidiolex is currently the poster child for a successful cannabinoid pharmaceutical; garnering over €430 million in sales in 2020 and serving an estimated patient population of more than 20,000. The story of GW Pharmaceuticals, the producers of Epidiolex, is instructive regarding the challenges and opportunities of operating in the pharmaceutical cannabis space; taking over 20 years to generate considerable sales and facing several setbacks in clinical trials. The fruits of GW’s strategy are obvious however, with sales increasing at a rapid pace, and the recent acquisition of the company by Jazz Pharmaceuticals for over €6 billion.

The current medical cannabis market is bursting with innovation. The author has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which could have a large impact on the medicinal cannabis space. Products with new routes of administration, such as metered inhalers and transdermal products, are currently making their way through the approvals process. Research and development on minor cannabinoids such as Cannabigerol (CBG) and Cannabichromene (CBC) is just beginning, with a lot of therapeutic promise but still with a lack of hard evidence.

Many in the medical cannabis space are developing portfolios of patents to protect products and their methods of production. The industry is yet to see a considerable amount of litigation, but this may soon change, as signalled by the case between GW Pharmaceuticals and Canopy Growth over proprietary methods of cannabinoid extraction. In the realm of patents, the looming expiration of market exclusivity on Epidiolex could soon offer opportunities to potential producers of generics to supply cheaper alternatives to patients suffering from rare forms of epilepsy.

Overall, the total potential for the use of medical cannabinoids in the pharmaceutical space has barely been scratched. In the medium to long term, the publisher expects to see the development of a range of new cannabinoid therapeutics approved across the globe. Operators in the space can expect to see these products gradually taking up more of the market share at the expense of unapproved flower and full-spectrum oils over the next 10 years. This will coincide with the liberalisation of adult-use cannabis across North America and Europe, which will further distill the use of medical products from flower to more precise formulations.

For more information about this report visit https://www.researchandmarkets.com/r/v1reck

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

You Might Also Like

IIPR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Innovative Industrial Properties, Inc. and Encourages Investors to Contact the Firm

Creators of Muscle Milk Launch New Hemp Infused Sports Nutrition Brand GYM WEED in U.S. Market

Curaleaf International Secures Two Further Licences at its Spanish GMP Facility to Increase Manufacturing Capacity of Medical Cannabis Extracts for European Market

INNOVATIVE INDUSTRIAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Innovative Industrial Properties, Inc. – IIPR

Applied UV Declares Monthly Preferred Stock Dividend

TAGGED: Business Wire

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[wpforms id="4115329"]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Business Wire December 23, 2021
Share this Article
Twitter Reddit Email Copy Link
Previous Article Cannabis Testing Industry Trends and Opportunities 2021-2028 – Increasing Awareness through Conferences, Symposia, and Workshops to Drive Growth – ResearchAndMarkets.com
Next Article 2021 Report on the Global Industrial Hemp Market – Look at Environmental Benefits of Hemp Cultivation – ResearchAndMarkets.com

You Might Also Like

IIPR DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Innovative Industrial Properties, Inc. and Encourages Investors to Contact the Firm

June 23, 2022

Creators of Muscle Milk Launch New Hemp Infused Sports Nutrition Brand GYM WEED in U.S. Market

June 22, 2022

Curaleaf International Secures Two Further Licences at its Spanish GMP Facility to Increase Manufacturing Capacity of Medical Cannabis Extracts for European Market

June 22, 2022

INNOVATIVE INDUSTRIAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Innovative Industrial Properties, Inc. – IIPR

June 22, 2022

Cannabis News and More

Work with an experienced cannabis media firm to provide your brand with the exposure it needs.

Cannabis Topics

  • Cannabis
  • Business
  • CBD
  • Cannabis Science
  • Culture & Arts

Company

  • About Maryjanes Post
  • Contact Cannabis Media
  • Contributor Guidelines

Terms of Use

  • TERMS
  • PRIVACY
  • CONTRIBUTOR AGREEMENT
  • DMCA

Resources

  • Write For UsNew
  • Cannabis Advertising
  • Cannabis Partnerships
  • Cannabis Press ReleaseNew
Cannabis NewsCannabis News
Follow US

© 2018 - 2022 MaryJanes Post Media. All Rights Reserved.

Go to mobile version
Welcome Back!

Sign in to your account

Lost your password?